Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your experience. Save up to 40% More details

Teva sees return to growth after opioid settlement, shares jump

Stock Markets Jul 27, 2022 01:57PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
© Reuters. FILE PHOTO: The logo of Teva Pharmaceutical Industries is seen during a news conference hold by its CEO, Kare Schultz, to discuss the company's 2019 outlooks in Tel Aviv, Israel February 19, 2019. REUTERS/Amir Cohen

By Steven Scheer

JERUSALEM (Reuters) -Teva Pharmaceutical Industries on Wednesday forecast mid-single digit revenue growth over the next five years as it strives to move on from its high debt and an overhang from thousands of lawsuits over its alleged role in the U.S. opioid crisis.

Israel-based Teva, the world's largest generic drugmaker, for the past five years has been hit hard by a weak U.S. generics market and stiff competition to its blockbuster multiple sclerosis drug Copaxone.

After years of negotiations, Teva on Tuesday proposed a $4.35 billion nationwide settlement - mostly cash and partly medicines - to resolve its opioid lawsuits..

Teva in May said it expected a $2.6 billion settlement but chief executive Kare Schultz said the figure rose during negotiations with plaintiffs.

The agreement in principle should take a few weeks to finalize and then it needs a host of approvals before it takes effect, Schultz said on Wednesday.

He said that under terms of the agreement, it will cost the company between $300 million and $400 million annually over 13 years - a sum shareholders deem as a relief as its shares were up more than 21%.

The state of New York has not agreed to participate in the settlement, and continues to seek a judgment against Teva after a New York jury found the company responsible for the state's opioid crisis in December.

Schultz told Reuters he expects Teva to reach a settlement with New York in the coming weeks, and that the value of the New York settlement would be included in the overall settlement of state and local government claims.

The deal "is the beginning of putting this behind us," Schultz earlier told analysts on a conference call.

"We have a very sustainable foundation, which means that we can return to growth in both our revenue and earnings," he said.

Schultz noted that growth in coming years will be driven by biosimilar products, along with its migraine drug Ajovy and Huntington's disease treatment Austedo, as well as increased generic volumes in the United States and Europe.

He added that Copaxone sales are likely to fall to $700 million in 2022, while Ajovy and Austedo combined are forecast to reach sales of $1.4 billion this year.

Truxima, Teva's biosimilar to for adults with non-Hodgkin lymphoma, has already reached a 25% market share with annual sales of $1 billion.

Schultz noted that drugs with sales that total nearly $200 billion will be coming off patent in the next five years and $400 billion in the next decade. Teva, he said, has 1,100 products in the pipeline to cover some 80% of those.

In addition to annualized growth of mid-double digits, Teva set targets to further reduce its debt and raise its operating income margin and cash-to-earnings by 2027. It paid down $15 billion of debt over the last five years to a level of $20 billion, and Teva foresees that falling to $12 billion in 2027.

For the full year, Teva expects revenue of up to $15.6 billion.

While Teva is not in a position for big moves, Schultz said it could make small product acquisitions to expand its portfolio, while at the same time continuing to consolidate its manufacturing sites.

"We will stay the world leader in generics," he said.

Teva sees return to growth after opioid settlement, shares jump

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

Write your thoughts here
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
Sign up with Email